First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan
المؤلفون المشاركون
Chuah, Seng-Kee
Lee, Chen-Hsiang
Yao, Chih-Chien
Tsai, Kai-Lung
Wang, Hsing-Ming
Tsai, Cheng-En
Huang, Chih-Fang
Chiu, Chien-Hua
Chiu, Yi-Chun
Wu, Keng-Liang
Kuo, Chung-Mou
Liang, Chih-Ming
Tai, Wei-Chen
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-12-11
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Aims.
Patients with chronic kidney disease (CKD) and Helicobacter pylori (H.
pylori) infection have a higher incidence of gastroduodenal diseases and therefore are recommended to receive eradication therapies.
This study aimed to assess the efficacy of a 7-day standard triple therapy in patients with CKD (eGFR < 60 ml/min/1.73 m2) and to investigate the clinical factors influencing the success of eradication.
Methods.
A total of 758 patients with H.
pylori infection receiving a 7-day standard first-line triple therapy between January 1, 2013, and December 31, 2014, were recruited.
Patients were divided into two groups: CKD group (N=130) and non-CKD group (N=628).
Results.
The eradication rates attained by the CKD and non-CKD groups were 85.4% and 85.7%, respectively, in the per-protocol analysis (p=0.933).
The eradication rate in CKD stage 3 was 84.5% (82/97), in stage 4 was 88.2% (15/17), and in those who received hemodialysis was 87.5% (14/16).
There were no significant differences in the various stages of CKD (p=0.982).
The adverse events were similar between the two groups (3.1% versus 4.6%, p=0.433).
Compliance between the two groups was good (100.0% versus 99.8%, p=0.649).
There was no significant clinical factor influencing the H.
pylori eradication rate in the non-CKD and CKD groups.
Conclusions.
This study suggests that the H.
pylori eradication rate and adverse rate in patients with CKD are comparable to those of non-CKD patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Liang, Chih-Ming& Chiu, Chien-Hua& Wang, Hsing-Ming& Tai, Wei-Chen& Yao, Chih-Chien& Tsai, Cheng-En…[et al.]. 2017. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. BioMed Research International،Vol. 2017, no. 2017, pp.1-7.
https://search.emarefa.net/detail/BIM-1136348
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Liang, Chih-Ming…[et al.]. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. BioMed Research International No. 2017 (2017), pp.1-7.
https://search.emarefa.net/detail/BIM-1136348
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Liang, Chih-Ming& Chiu, Chien-Hua& Wang, Hsing-Ming& Tai, Wei-Chen& Yao, Chih-Chien& Tsai, Cheng-En…[et al.]. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. BioMed Research International. 2017. Vol. 2017, no. 2017, pp.1-7.
https://search.emarefa.net/detail/BIM-1136348
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1136348
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر